Diamyd Medical AB - Class B DMYD B

STO: DMYD B | ISIN: SE0005162880 5/05/2025

9,370 SEK (-7,23%)

(-7,23%) 5/05/2025

Grafiek Diamyd Medical AB - Class B

Grafiek Diamyd Medical AB - Class B

1 dag1d -7,23%
1 week1w 0,00%
1 maand1m 18,76%
3 maanden3m -42,87%
6 maanden6m -27,02%
1 jaar1j -19,91%
5 jaar5j -58,81%

Diamyd Medical AB - Class B in het nieuws

Toon enkel gratis nieuws

21 april 2025 · Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout · Persbericht

9 september 2024 · Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine · Persbericht

30 juli 2024 · Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes · Persbericht

23 juli 2024 · Diamyd Medical receives positive feedback from FDA on potential Accelerated Approval for Diamyd® in Type 1 Diabetes · Persbericht

18 juli 2024 · Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes · Persbericht

12 april 2024 · Recruitment milestone reached in Diamyd® Phase 3 trial · Persbericht

15 februari 2024 · Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd® · Persbericht

8 januari 2024 · Diamyd Medical gains market research findings to guide U.S. commercial strategy · Persbericht

7 november 2023 · Diamyd Medical partners with DiaUnion to recruit participants for Type 1 diabetes prevention trial · Persbericht

17 oktober 2023 · Diamyd Medical announces a webcast presentation on October 20 regarding its industry partnership with JDRF · Persbericht

Profiel Diamyd Medical AB - Class B

CEO: Ulf Hannelius

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe